ALPHA-INTERFERON THERAPY FOR ESSENTIAL THROMBOCYTHAEMIA

F. J. Giles*, A. G. Gray, M. Brozovic, I. R. Grant, S. J. Machin, J. D M Richards, S. Venutas, C. R J Singer, K. L. Yong, S. C. Davies, A. V. Hoffbrand, A. B. Mehta, M. J G Thomas, A. H. Goldstone

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

85 Scopus citations

Abstract

18 patients with symptomatic essential thrombocythaemia were treated with recombinant alpha interferon (2a or 2b). Subcutaneous dosage regimens, which were well-tolerated, selectively lowered the platelet count and relieved symptoms in all patients, whether previously treated or untreated. Recombinant alpha-interferon may offer a nonleukaemogenic alternative therapy for these patients.

Original languageEnglish (US)
Pages (from-to)70-72
Number of pages3
JournalThe Lancet
Volume332
Issue number8602
DOIs
StatePublished - Jul 9 1988

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'ALPHA-INTERFERON THERAPY FOR ESSENTIAL THROMBOCYTHAEMIA'. Together they form a unique fingerprint.

Cite this